Arcutis Biotherapeutics, Inc. Common Stock
ARQT US03969K1088
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -27% | -35% | -78% | 306% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Edwards Larry Todd O |
19.99 USD |
4,207 Sold |
84,092 USD |
02/10/2025 | 02/10/2025 |
| Watanabe Todd O |
20.04 USD |
20,739 Sold |
415,574 USD |
01/10/2025 | 02/10/2025 |
| Edwards Larry Todd O |
20.78 USD |
297 Sold |
6,172 USD |
02/10/2025 | 02/10/2025 |
| Welgus Howard G. O |
18.92 USD |
9,538 Sold |
180,485 USD |
01/10/2025 | 01/10/2025 |
| Watanabe Todd O |
20.02 USD |
9,261 Sold |
185,372 USD |
01/10/2025 | 01/10/2025 |
| Welgus Howard G. O |
18.92 USD |
462 Sold |
8,742 USD |
01/10/2025 | 01/10/2025 |
| Watanabe Todd O |
18.91 USD |
15,000 Sold |
283,703 USD |
01/10/2025 | 01/10/2025 |
| Watanabe Todd O |
17.52 USD |
504 Sold |
8,829 USD |
08/09/2025 | 09/09/2025 |
| Watanabe Todd O |
17.54 USD |
9,625 Sold |
168,799 USD |
08/09/2025 | 08/09/2025 |
| Matsuda Masaru O |
16.16 USD |
36,130 Sold |
583,716 USD |
04/09/2025 | 04/09/2025 |